Table 1.
Overall | H-Y ≥ 3.0 n=53 |
H-Y < 3.0 n=68 |
P | |
---|---|---|---|---|
Age (years) | 66.46 ± 8.57 | 67.25 ± 8.64 | 65.84 ± 8.52 | 0.37 |
Age at onset (years) | 53.70 ± 8.53 | 54.21 ± 8.49 | 53.31 ± 8.61 | 0.57 |
Sex, Male, n (%) | 67 (55.37) | 25 (47.17) | 42 (61.76) | 0.11 |
Disease duration (years) | 12.84 ± 2.92 | 13.25 ± 2.87 | 12.53 ± 2.93 | 0.07 |
Asymmetry (left), n (%) | 73 (60.33) | 33 (62.26) | 40 (58.82) | 0.70 |
Hoehn &Yahr stage | 2.70 ± 0.77 | 3.40 ± 0.57 | 2.16 ± 0.35 | <0.01* |
UPDRS-I score | 3.95 ± 2.42 | 4.85 ± 2.54 | 3.25 ± 2.08 | <0.01* |
UPDRS-II score | 17.17 ± 6.25 | 20.15 ± 5.96 | 14.84 ± 5.47 | <0.01* |
UPDRS-III score | 34.31 ± 11.89 | 38.66 ± 11.71 | 30.93 ± 10.97 | <0.01* |
Motor fluctuations, n (%) | 78 (64.46) | 39 (73.58) | 39 (57.35) | 0.06 |
Dyskinesia, n (%) | 28 (23.14) | 13 (24.53) | 15 (22.06) | 0.75 |
TD phenotype, n (%) | 26 (21.49) | 4 (7.55) | 22 (32.35) | <0.01* |
PIGD phenotype, n (%) | 78 (64.46) | 39 (73.58) | 39 (57.35) | 0.06 |
Intermediate, n (%) | 17 (14.05) | 10 (18.87) | 7 (10.29) | 0.18 |
FOG, n (%) | 75 (61.98) | 44 (83.02) | 31 (45.59) | <0.01* |
ABC (%) | 64.40 ± 26.64 | 50.25 ± 27.99 | 75.42 ± 19.52 | <0.01* |
Standardized TUG | 19.98 ± 21.88 | 28.82 ± 30.67 | 13.47 ± 6.83 | <0.01* |
LED (mg) | 954.52 ± 359.69 | 1033.40 ± 326.46 | 893.05 ± 374.50 | 0.03* |
PDSS | 98.79 ± 26.83 | 92.64 ± 26.24 | 103.59 ± 26.48 | 0.03* |
ESS | 8.40 ± 6.24 | 8.21 ± 5.75 | 8.54 ± 6.63 | 0.77 |
SS-16 | 5.42 ± 3.19 | 4.91 ± 3.36 | 5.82 ± 3.02 | 0.12 |
RBDSQ | 5.87 ± 2.66 | 6.06 ± 2.53 | 5.72 ± 2.77 | 0.49 |
HAMA | 14.48 ± 9.28 | 16.66 ± 9.74 | 12.78 ± 8.59 | 0.02* |
HAMD | 10.79 ± 6.20 | 13.04 ± 6.46 | 9.03 ± 5.42 | <0.01* |
FSS | 42.32 ± 18.01 | 46.21 ± 16.62 | 39.29 ± 18.57 | 0.03* |
MMSE | 26.11 ± 4.00 | 25.74 ± 4.00 | 26.40 ± 4.00 | 0.15 |